Tecemotide
As of the edition of 20 October 2026, Tecemotide is a protein: went quiet in 2019; acts on MUC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2019
- Kind
- Protein
- Registered trials
- 13, 4 stopped early
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Digestive system; Heart and blood vessels; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MUC1 | Mucin-1 | P15941 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 8 | 8 | 0 | 0 |
| Phase 3 | 3 | 1 | 0 | 2 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2000 to now |